1. Home
  2. RZLT vs MDXH Comparison

RZLT vs MDXH Comparison

Compare RZLT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

N/A

Current Price

$2.02

Market Cap

187.3M

Sector

Health Care

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$3.22

Market Cap

167.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RZLT
MDXH
Founded
2010
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.3M
167.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RZLT
MDXH
Price
$2.02
$3.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$12.33
$7.67
AVG Volume (30 Days)
12.2M
126.0K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$1.07
$1.35
52 Week High
$11.46
$5.33

Technical Indicators

Market Signals
Indicator
RZLT
MDXH
Relative Strength Index (RSI) 25.06 32.57
Support Level $1.07 $3.25
Resistance Level $1.85 $3.40
Average True Range (ATR) 0.64 0.17
MACD -0.94 0.00
Stochastic Oscillator 9.26 14.29

Price Performance

Historical Comparison
RZLT
MDXH

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: